Eluxadoline Eases Pain and Diarrhea for Some With IBS

Share this content:
Eluxadoline Eases Pain and Diarrhea for Some With IBS
Eluxadoline Eases Pain and Diarrhea for Some With IBS

THURSDAY, Jan. 21, 2016 (HealthDay News) -- Eluxadoline (Viberzi) for irritable bowel syndrome (IBS) with diarrhea seems to reduce symptoms for some patients for at least six months, according to research published in the Jan. 21 issue of the New England Journal of Medicine. Based on these findings, eluxadoline was approved recently by the U.S. Food and Drug Administration.

Anthony Lembo, M.D., an associate professor of medicine at Harvard Medical School in Boston, and colleagues randomly assigned 2,427 adults with IBS with diarrhea to one of two doses of eluxadoline or a placebo. In one trial, patients took eluxadoline twice a day for 26 weeks, and in the other trial they took the drug for 52 weeks.

The researchers found that by the 12th week of the trials, between 25 and 30 percent of patients taking the highest dose of the drug (100 mg twice daily) saw improvement in their symptoms, compared with 16 to 17 percent of those taking the placebo. These results remained similar when assessed again at 26 weeks. The most common side effects of eluxadoline were nausea, constipation, and abdominal pain. The most serious side effect of eluxadoline was pancreatitis.

Eluxadoline shouldn't be used in patients with a history of bile duct obstruction, severe liver impairment, or severe constipation, or in patients who drink more than three alcoholic beverages a day, according to the FDA.

The study was funded by Furiex Pharmaceuticals, an affiliate of Allergan, the manufacturer of eluxadoline.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »